Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03462914
Other study ID # CPA-petroclival meningiomas
Secondary ID
Status Not yet recruiting
Phase N/A
First received March 1, 2018
Last updated March 12, 2018
Start date March 15, 2018
Est. completion date May 1, 2019

Study information

Verified date March 2018
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

• Give an effective treatment for CPA-petroclival meningiomas and can detect the best approach for these tumors.

. Improve the outcome of these patients and decease rate of recurrence.


Description:

There are several lesions arising in the petroclival region. The most frequent tumor is the petroclival meningioma, followed by chondrosarcomas, chordomas, schwannomas of the cranial nerves V and VII, and other malignant tumors [1, 2, 3, 4, 5].

Petroclival meningiomas are tumors of the skull base that present a formidable challenge to surgical resection because of their deep location and relationship to vital neurovascular structures. In the majority of the cases they are benign tumors, but may involve or infiltrate the skull base bone, the dura mater, the brainstem, and all important neurovascular structures of this region. The petroclival region comprises the anatomical location of the body of the sphenoid bone, the anterior central portion of the occipital bone, and is bordered on the lateral aspect by the petrous apex. The roof of this space is formed by the petroclival ligaments and the tentorium. This space contains important neurovascular structures that are frequently involved or displaced by the tumor in a variable pattern. The basilar artery with its branches may be embedded or displaced by the meningioma. The petrosal vein is often displaced posteriorly by the tumor. Cranial nerves III and IV are usually displaced upwardly and the nerve VI is often surrounded by tumor. Petroclival meningiomas have their origin medial to cranial nerves V, VII, VIII, IX, X, and XI, and reach the tentorium . They frequently extend to the middle cranial fossa, cavernous sinus, prepontine space, and down to the foramen magnum. These tumors frequently compress the brainstem making total removal very difficult or impossible without neurologic deficits. cerebellopontine angle (CPA) and low clivus meningiomas may reach these areas. These lesions usually need different surgical approaches as transpetrosal approach ( anterior, modified and combined ) and retrosigmoid approach


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date May 1, 2019
Est. primary completion date April 1, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patient with a single lesion .

- Patient with a denovo lesion.

Exclusion Criteria:

- Patient with recurrent lesions.

- Patient with lesions after adjuvant therapy.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Spetzler RF, Hamilton MG, Daspit CP. Petroclival lesions. Clin Neurosurg. 1994;41:62-82. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The success rate of surgery complete resection of the tumor 1 year
See also
  Status Clinical Trial Phase
Completed NCT02810899 - Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Phase 4
Withdrawn NCT00977795 - A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors Phase 1/Phase 2
Recruiting NCT00787982 - Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors Phase 1/Phase 2
Withdrawn NCT00555984 - Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors N/A
Completed NCT00038441 - Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas Phase 1/Phase 2
Recruiting NCT03619694 - Role of MR Spectroscopy in Brain Tumors
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Unknown status NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT01244737 - FLT-PET Imaging of Brain Tumors in Children Phase 2
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Terminated NCT00769093 - Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy Phase 1
Completed NCT00392119 - MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors Phase 1
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Terminated NCT00038389 - Study of Vioxx and Radiation Therapy for Brainstem Glioma Phase 1
Recruiting NCT05049148 - Platelets Activation in Brain Neoplasms N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT04712721 - Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Early Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Terminated NCT01954576 - NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A
Recruiting NCT05538130 - A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors Phase 1